Login to Your Account

Eye, Eye: Xoma Raising $25.5M While Phase III Uveitis Push Continues

By Randy Osborne
Staff Writer

Tuesday, August 20, 2013
Marching ahead with its platform that finds monoclonal antibody binders to allosteric sites on receptors and ligands, Xoma Corp. priced a public stock sale of 7.5 million shares at $3.62, the previous day's closing bid, as investors await Phase III data on gevokizumab for uveitis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription